← All trials
NCT05959421
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2024
- Primary completion
- Mar 31, 2026
- Completion date
- Feb 28, 2027
- First posted
- Jul 25, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of HamburgLead sponsor
- University of HamburgOverall official - principal investigator
- Bernhard Nocht Institute for Tropical MedicineCollaborator
- J. W. Goethe UniversityCollaborator
- German Federal Ministry of Education and ResearchCollaborator
- Monipol Deutschland GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.